Search results for "loma"

showing 10 items of 1142 documents

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

2016

Abstract Purpose: The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug resistance, their potential activity as drug-sensitizing agents has not yet been investigated in multiple myeloma. Experimental Design: Here we studied the potential utility of miR-221/222 inhibition in sensitizing refractory multiple myeloma cells to melphalan. Results: miR-221/222 expression inversely correlated with melphalan sensitivity of multiple myeloma cells. Inhibition of miR-221/222 overcame melphalan resistance and triggered apoptosis of multiple myeloma cells in vitro, in the presence or absence of…

0301 basic medicineMelphalanCancer ResearchStromal cellApoptosisDrug resistancePharmacologyArticle03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinemyeloma microRNA mir-221 melphalanimmune system diseasesIn vivohemic and lymphatic diseasesCell Line TumorProto-Oncogene ProteinsmedicineAnimalsHumansMelphalanMultiple myelomaNOD miceCell Proliferationbusiness.industryCancermedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation NeoplasticMicroRNAs030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisGrowth inhibitionMultidrug Resistance-Associated ProteinsbusinessApoptosis Regulatory ProteinsMultiple Myelomamedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

'Secondary prevention' against female HPV infection: literature review of the role of carrageenan.

2020

Introduction: Human papillomaviruses (HPVs) are common sexually transmitted pathogens, causally associated with cervical cancer and other anogenital cancers, as well as approximately 20% of head and neck cancers. The HPV vaccine is an exceptional primary prevention tool, but the question of adequate secondary-prevention strategies remains open. The aim of this review is to better clarify the role of carrageenan in HPV prevention-strategies. Areas covered: A comprehensive literature search was performed (PubMed/MEDLINE, Embase, Google Scholar, Cochrane Databases) to identify articles on the use of carrageenan against HPV infection. The studies were identified using combinations of the search…

0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_treatment030106 microbiologyCarrageenan papillomavirus prevention HPV microbicideMEDLINEAlphapapillomavirusBioinformaticsCarrageenanMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemVirologyMicrobicidemedicineSecondary PreventionAnimalsHumans030212 general & internal medicinePapillomavirus VaccinesCervical cancerbusiness.industryMechanism (biology)Papillomavirus InfectionsHPV infectionmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaCarrageenanInfectious DiseaseschemistryFemalebusinessAdjuvantExpert review of anti-infective therapy
researchProduct

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

2016

AbstractMultiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis, bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine pathways as the most progressively affected during disease evolution. We then sel…

0301 basic medicineOncologyAdultMaleCandidate genemedicine.medical_specialtyBiologyIFNCCL503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMultiple myelomaAgedAged 80 and overInflammationHematologyComputational BiologyHematologyMiddle Agedmedicine.diseaseNeoplasm ProteinsGene expression profilingGene Expression Regulation Neoplasticmyeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologygene expressionDisease ProgressionOriginal ArticleFemaleIL17ABone marrowMultiple MyelomaTranscriptomeMonoclonal gammopathy of undetermined significanceSignal TransductionBlood Cancer Journal
researchProduct

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

2016

Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival.A prespecifie…

0301 basic medicineOncologyMaleAntigens CD38Drug ResistanceDexamethasoneIxazomibBortezomibchemistry.chemical_compound0302 clinical medicineRecurrenceMonoclonalAntineoplastic Combined Chemotherapy ProtocolsMedicineInfusions IntravenouElotuzumabInfusions IntravenousMultiple myelomaIsatuximabBortezomibMedicine (all)SLAMF7Antibodies MonoclonalGeneral MedicineMiddle Aged030220 oncology & carcinogenesisFemaleIntravenousMultiple MyelomaHumanmedicine.drugAdult; Aged; Antibodies Monoclonal; Antigens CD38; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance Neoplasm; Female; Humans; Infusions Intravenous; Male; Middle Aged; Multiple Myeloma; Recurrence; Medicine (all)AdultInfusionsmedicine.medical_specialtyAntibodiesDisease-Free Survival03 medical and health sciencesInternal medicineHumansAntigensAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryDaratumumabInterim analysismedicine.diseaseADP-ribosyl Cyclase 1Surgery030104 developmental biologychemistryDrug Resistance NeoplasmNeoplasmbusinessCD38The New England journal of medicine
researchProduct

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

2020

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pem…

0301 basic medicineOncologyMelphalanCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdverse effectMultiple myelomaPneumonitisbusiness.industryLate effectImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuation030104 developmental biologymyelomaOncology030220 oncology & carcinogenesispembrolizumabimmunotherapymedicine.symptombusinessconsolidationmedicine.drug
researchProduct

Genomic landscape analyses in cervical carcinoma and consequences for treatment.

2020

Where we are on the road to ‘tailor-made’ precision medicine for drug-resistant cervical carcinoma? We explored studies about analyses of viral and human genomes, epigenomes and transcriptomes, DNA mutation analyses, their importance in detecting HPV sequences, mechanisms of drug resistance to established and targeted therapies with small molecule or therapeutic antibodies, to radiosensitivity and to chemoradiotherapy. The value of repurposing of old drugs initially approved for other disease indications and now considered for cervix cancer therapy is also discussed. The microbiome influences drug response and survival too. HPV genomic integration sites were less significant. Nomograms (Lee…

0301 basic medicineOncologymedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseDrug resistance030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansMicrobiomeCervixPapillomaviridaeRepurposingPharmacologybusiness.industryDNAGenomicsPrecision medicinePrognosis030104 developmental biologymedicine.anatomical_structureHuman genomeFemalebusinessChemoradiotherapyCurrent opinion in pharmacology
researchProduct

Multidisciplinary surgical management of Cowden syndrome: Report of a case

2016

Cowden’s Syndrome (CS) is a rare congenital autosomal dominant disorder that affects around 1/200000 patients with an incomplete penetrance and variable expressivity, characterized by alterations in a tumor suppressor gene. A 14-year-old Caucasian male patient came to the attention of the authors complaining of palm nodules, gingival bleeding and painful pedunculated lesions on the lips and on the labial side of anterior sextants. After genetic investigation the final diagnosis of a Cowden Syndrome was made. The lesions were surgically removed under general anesthesia and no clinical signs of recurrence were found three months after surgical excision. Considering the severe symptoms of the …

0301 basic medicineOral papillomatosismedicine.medical_specialtyOdontologíaOral papillomatosisCancer predispositionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciences0302 clinical medicineCancer predisposition; Case report; Early diagnosis; Multiple hamartoma syndrome; Oral papillomatosis; Dentistry (all)Case reportmedicineGeneral Dentistrybusiness.industryCancer predispositionMultiple hamartoma syndromeMultiple hamartoma syndrome030206 dentistryCowden syndromeEarly diagnosismedicine.diseaseCiencias de la saludPenetranceDermatologySurgery030104 developmental biologyMale patientDentistry (all)UNESCO::CIENCIAS MÃ DICASOdontostomatology for the Disabled or Special PatientsSurgical excision:CIENCIAS MÃ DICAS [UNESCO]businessJournal of Clinical and Experimental Dentistry
researchProduct

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

2018

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Specifically, the binding with PD-1 ligand (PD-L1) on the surface of tumor plasma cells down-regulates T cell-proliferation, thus contributing to the immune escape of tumor cells. In relapsed and/or refr…

0301 basic medicinePD-L1lcsh:Immunologic diseases. AllergyDurvalumabMini ReviewT-LymphocytesT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationT cellsPembrolizumabmedicine.disease_causeB7-H1 Antigen03 medical and health sciences0302 clinical medicineBone Marrowimmune dysregulationPD-L1PD-1Tumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyImmune dysregulation; Multiple myeloma; PD-1; PD-L1; T cells; Animals; B7-H1 Antigen; Bone Marrow; Humans; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tumor MicroenvironmentMultiple myelomabiologybusiness.industryImmune dysregulationmedicine.diseasemultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCancer researchNivolumabbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Detection of human papillomavirus DNA in formalin-fixed, paraffin-embedded squamous papillomas of the oral cavity

2018

Background Squamous papillomas are exophytic proliferations of surface oral epithelium. Human papillomavirus (HPV) infection is widely accepted as the etiology of squamous papillomas however the virus cannot be detected in a significant percentage of lesions. Material and methods Using polymerase chain reaction (PCR), we tested 35 formalin-fixed paraffin-embedded (FFPE) squamous papillomas for the presence of HPV DNA. Results Six papillomas (17%) tested positive for HPV DNA; four contained HPV-6 and two contained HPV-11. Given that β-globin DNA was only identified in half of the samples, DNA degradation appears to have significantly impacted the results. Conclusions The results likely repre…

0301 basic medicinePathologymedicine.medical_specialtyFormalin fixed paraffin embeddedOral cavityViruslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawHuman papillomavirus DNAmedicineGeneral DentistryPolymerase chain reactionOral Medicine and Pathologybusiness.industryResearchHPV infectionvirus diseases:CIENCIAS MÉDICAS [UNESCO]medicine.diseasefemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASPapillomabusinessDNAJournal of Clinical and Experimental Dentistry
researchProduct

Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal pap…

2017

Lesions affecting anogenital mammary-like glands (AGMLG) are histopathologically very similar to those seen in the breast but whether this morphological similarity is also reflected at the genetic level is unknown. To compare the underlying molecular mechanisms in lesions of AGMLG and their mammary counterparts, we analyzed the mutational profile of 16 anogenital neoplasms including 5 hidradenomas papilliferum (HP), 1 lesion with features of HP and fibroadenoma (FA), 7 FA, 3 phyllodes tumors (PhT)) and 18 analogous breast lesions (6 intraductal papillomas (IDP), 9 FA, and 3 PhT) by high-coverage next generation sequencing (NGS) using a panel comprising 50 cancer-related genes. Additionally,…

0301 basic medicinePathologymedicine.medical_specialtyHidradenomaClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsBiologyPathology and Forensic MedicineVulvaMED12Papilloma IntraductalLesionPhosphatidylinositol 3-Kinases03 medical and health sciencessymbols.namesake0302 clinical medicinePhyllodes TumorIntraductal papillomamedicineHumansBreastAgedSanger sequencingVulvar NeoplasmsHigh-Throughput Nucleotide SequencingPhyllodes tumorGeneral MedicineMiddle Agedmedicine.diseaseFibroadenomaTubular Sweat Gland Adenomas030104 developmental biologymedicine.anatomical_structureFibroadenoma030220 oncology & carcinogenesisMutationsymbolsFemalemedicine.symptomAnnals of Diagnostic Pathology
researchProduct